Beta-Blocker / Ovarian - Full Text View - ClinicalTrials.gov
Beta-Blocker / Ovarian
This study is currently recruiting participants.
Verified March 2012 by M.D. Anderson Cancer Center
First Received on January 3, 2012.
Last Updated on March 9, 2012
History of Changes
| Sponsor: | M.D. Anderson Cancer Center |
|---|---|
| Information provided by (Responsible Party): | M.D. Anderson Cancer Center ( M.D. Anderson Cancer Center ) |
| ClinicalTrials.gov Identifier: | NCT01504126 |
Purpose
The
goal of this clinical research study is to learn if it is feasible to
give a beta-blocker such as Inderal (propranolol hydrochloride) with
standard chemotherapy (paclitaxel and carboplatin or possibly docetaxel)
to treat ovarian cancer. The safety of propranolol hydrochloride will also be studied.
Propranolol hydrochloride
is designed to block certain chemicals that affect the heart.
Researchers want to learn if this might also boost the immune system,
allowing the chemotherapy to be more effective.
Paclitaxel is designed to block cancer cells from dividing, which may cause them to die.
Carboplatin is designed to interfere with the growth of cancer cells by stopping cell division, which may cause the cells to die.
